FOCALIN XR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FOCALIN XR (FOCALIN XR).

How it works

Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.

What the body does with it

Metabolism	Primarily metabolized via de-esterification to the major inactive metabolite d-ritalinic acid. Minor pathways include hydroxylation and oxidation, mediated by cytochrome P450 enzymes (CYP2D6, CYP3A4 are not major contributors).
Excretion	Renal (approximately 90% as unchanged drug and metabolites)
Half-life	Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Protein binding	Protein binding: ~15%, primarily to albumin
Volume of Distribution	Vd: 1.5 L/kg
Bioavailability	Oral: 95% (FOCALIN XR)
Onset of Action	Oral: 0.5-1 hour for extended-release
Duration of Action	8-12 hours for extended-release formulation

Classification & Brands

Dosing & administration

Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	GFR 30-89 mL/min: no adjustment. GFR <30 mL/min: reduce dose by 50%. Hemodialysis: administer after dialysis.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Pediatric use	Children ≥6 years: initial 5-10 mg orally once daily; increase by 5-10 mg weekly; max 60 mg/day. Weight-based: 0.3-0.5 mg/kg/day.
Geriatric use	Start at 5 mg orally once daily; increase slowly; monitor for cardiovascular effects and insomnia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FOCALIN XR (FOCALIN XR).

Breastfeeding	No human data; M/P ratio unknown. Methylphenidate is excreted into breast milk in small amounts; potential for infant agitation and insomnia. Not recommended during breastfeeding.
Teratogenic Risk	Pregnancy Category C. First trimester: Insufficient human data; animal studies show increased fetal resorptions and skeletal abnormalities at high doses. Second/third trimesters: Risk of preterm delivery, low birth weight, and neonatal withdrawal (irritability, dysphoria). Use only if benefit justifies risk.

Warnings & precautions

■ FDA Black Box Warning

Focalin XR has a high potential for abuse and dependence. Prolonged use may lead to tolerance, psychological dependence, and withdrawal effects. It should be prescribed cautiously, especially in patients with a history of substance abuse.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to dexmethylphenidate or any component of the formulation.","Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis risk).","Glaucoma.","Motor tics or family history of Tourette's syndrome.","Severe anxiety, tension, agitation.","Patients with a history of drug dependence or alcoholism."]

Clinical Precautions

Precautions

["Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.","Blood pressure and heart rate increase: monitor for tachycardia and hypertension.","Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, new psychotic or manic symptoms, aggression.","Seizures: use with caution in patients with seizure disorders.","Long-term suppression of growth: monitor height and weight in pediatric patients.","Peripheral vasculopathy, including Raynaud's phenomenon.","Serotonin syndrome: risk when co-administered with serotonergic drugs."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FOCALIN XR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FOCALIN XR (FOCALIN XR).

How it works

What the body does with it

Metabolism	Primarily metabolized via de-esterification to the major inactive metabolite d-ritalinic acid. Minor pathways include hydroxylation and oxidation, mediated by cytochrome P450 enzymes (CYP2D6, CYP3A4 are not major contributors).
Excretion	Renal (approximately 90% as unchanged drug and metabolites)
Half-life	Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Protein binding	Protein binding: ~15%, primarily to albumin
Volume of Distribution	Vd: 1.5 L/kg
Bioavailability	Oral: 95% (FOCALIN XR)
Onset of Action	Oral: 0.5-1 hour for extended-release
Duration of Action	8-12 hours for extended-release formulation

Classification & Brands

Dosing & administration

Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	GFR 30-89 mL/min: no adjustment. GFR <30 mL/min: reduce dose by 50%. Hemodialysis: administer after dialysis.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Pediatric use	Children ≥6 years: initial 5-10 mg orally once daily; increase by 5-10 mg weekly; max 60 mg/day. Weight-based: 0.3-0.5 mg/kg/day.
Geriatric use	Start at 5 mg orally once daily; increase slowly; monitor for cardiovascular effects and insomnia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FOCALIN XR (FOCALIN XR).

Breastfeeding	No human data; M/P ratio unknown. Methylphenidate is excreted into breast milk in small amounts; potential for infant agitation and insomnia. Not recommended during breastfeeding.
Teratogenic Risk	Pregnancy Category C. First trimester: Insufficient human data; animal studies show increased fetal resorptions and skeletal abnormalities at high doses. Second/third trimesters: Risk of preterm delivery, low birth weight, and neonatal withdrawal (irritability, dysphoria). Use only if benefit justifies risk.